Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II
- DOI
- 10.1007/s13555-025-01465-4
- Published
- 2025-07-13
- Container
- Dermatology and Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-025-01465-4,
title = {Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I\&II},
author = {Vivian Y. Shi and John R. Ingram and Hadar Lev-Tov and Sylke Schneider-Burrus and Seth Forman and Martina L. Porter and Koremasa Hayama and Linnea Thorlacius and Jérémy Lambert and Tom Vaux and Bartosz Lukowski and Robert L. Rolleri and Jacek C. Szepietowski},
year = {2025},
journal = {Dermatology and Therapy},
doi = {10.1007/s13555-025-01465-4},
url = {https://doi.org/10.1007/s13555-025-01465-4}
}RIS
TY - JOUR TI - Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II AU - Vivian Y. Shi AU - John R. Ingram AU - Hadar Lev-Tov AU - Sylke Schneider-Burrus AU - Seth Forman AU - Martina L. Porter AU - Koremasa Hayama AU - Linnea Thorlacius AU - Jérémy Lambert AU - Tom Vaux AU - Bartosz Lukowski AU - Robert L. Rolleri AU - Jacek C. Szepietowski PY - 2025 JO - Dermatology and Therapy DO - 10.1007/s13555-025-01465-4 UR - https://doi.org/10.1007/s13555-025-01465-4 ER -
APA
Shi, V. Y., Ingram, J. R., Lev-Tov, H., Schneider-Burrus, S., Forman, S., Porter, M. L., Hayama, K., Thorlacius, L., Lambert, J., Vaux, T., Lukowski, B., Rolleri, R. L., & Szepietowski, J. C. (2025). Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatology and Therapy. https://doi.org/10.1007/s13555-025-01465-4
Source records
- crossref · retrieved 2026-09-27T06:57:35.028Z